Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.

[1]  I. Gilbert,et al.  Evaluation of three novel azasterols against Toxoplasma gondii. , 2011, Veterinary parasitology.

[2]  E. Ferro,et al.  Evaluation of vertical transmission of Toxoplasma gondii in Calomys callosus model after reinfection with heterologous and virulent strain. , 2011, Placenta.

[3]  R. Malik,et al.  Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. , 2011, Veterinary microbiology.

[4]  J. Silva,et al.  Toxoplasma gondii: the severity of toxoplasmic encephalitis in C57BL/6 mice is associated with increased ALCAM and VCAM-1 expression in the central nervous system and higher blood-brain barrier permeability. , 2010, Experimental parasitology.

[5]  N. Speybroeck,et al.  Chemosensitization of Trypanosoma congolense Strains Resistant to Isometamidium Chloride by Tetracyclines and Enrofloxacin , 2010, PLoS neglected tropical diseases.

[6]  C. González,et al.  Enrofloxacin-based therapeutic strategy for the prevention of endometritis in susceptible mares. , 2009, Journal of veterinary pharmacology and therapeutics.

[7]  E. Breitschwerdt,et al.  Comparative Activity of Pradofloxacin, Enrofloxacin, and Azithromycin against Bartonella henselae Isolates Collected from Cats and a Human , 2009, Journal of Clinical Microbiology.

[8]  E. Ferro,et al.  Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). , 2009, Placenta.

[9]  E. Ferro,et al.  Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. , 2009, Experimental parasitology.

[10]  R. Gazzinelli,et al.  The role of MHC haplotypes H2d/H2b in mouse resistance/susceptibility to cyst formation is influenced by the lineage of infective Toxoplasma gondii strain. , 2008, Anais da Academia Brasileira de Ciencias.

[11]  E. Ferro,et al.  Susceptibility to vertical transmission of Toxoplasma gondii is temporally dependent on the preconceptional infection in Calomys callosus. , 2007, Placenta.

[12]  K. Uney,et al.  Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits. , 2007, Research in veterinary science.

[13]  P. McDermott,et al.  Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. , 2006, Veterinary journal.

[14]  A. Oliveira,et al.  Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. , 2006, Experimental parasitology.

[15]  Uwe Groß,et al.  Subversion of innate and adaptive immune responses by Toxoplasma Gondii , 2006, Parasitology Research.

[16]  C. F. Alves,et al.  Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. , 2005, Parasite.

[17]  Amy C Anderson,et al.  Targeting DHFR in parasitic protozoa. , 2005, Drug discovery today.

[18]  B. Høgh,et al.  Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine , 2005, European Journal of Pediatrics.

[19]  H. Sager,et al.  Toltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant mice , 2004, Parasitology.

[20]  W. de Souza,et al.  Selective anti-Toxoplasma gondii activities of azasterols. , 2004, International journal of antimicrobial agents.

[21]  Kami Kim,et al.  Toxoplasma gondii: the model apicomplexan. , 2004, International journal for parasitology.

[22]  E. Candolfi,et al.  Immune response to Toxoplasma gondii. , 2004, Annali dell'Istituto superiore di sanita.

[23]  O. Kurt,et al.  Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. , 2003, Acta tropica.

[24]  E. Bevilacqua,et al.  Effect of Toxoplasma gondii Infection Kinetics on Trophoblast Cell Population in Calomys callosus, a Model of Congenital Toxoplasmosis , 2002, Infection and Immunity.

[25]  M. Ferreira,et al.  Some aspects of protozoan infections in immunocompromised patients- a review. , 2002, Memorias do Instituto Oswaldo Cruz.

[26]  R. Gibbs,et al.  Congenital Toxoplasmosis: A Review , 2001, Obstetrical & gynecological survey.

[27]  A. Sher,et al.  IL-10 Is Required for Prevention of Necrosis in the Small Intestine and Mortality in Both Genetically Resistant BALB/c and Susceptible C57BL/6 Mice Following Peroral Infection with Toxoplasma gondii1 , 2000, The Journal of Immunology.

[28]  U. Groß,et al.  Stage differentiation of the protozoan parasite Toxoplasma gondii. , 1999, Immunobiology.

[29]  C. Hunter,et al.  Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii , 1997, Infection and immunity.

[30]  A. Sher,et al.  In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. , 1996, Journal of immunology.

[31]  U. Hadding,et al.  Anti‐parasitic effector mechanisms in human brain tumor cells: Role of interferon‐γ and tumor necrosis factor‐α , 1996 .

[32]  I. Eperon,et al.  The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. , 1994, Journal of molecular biology.

[33]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.